DIAH

DIAH 2026

19 – 21 May 2026 | Bruges, Belgium

Guangcai Ren

Vet-Bio Vice President

Canton Biologics Co., Ltd.

Guangzhou, China

7 profile visitsCompanies/Industry

Ph.D. in Biotechnology, Sun Yat-sen University. Served at Wens Food Group for nearly 9 years. Currently in charge of the R&D of veterinary biological products at Canton Biologics.

My organisation

Welcome to the Canton Biologics booth — we're at B9! Canton Biologics is a globally integrated CDMO, operating four core sites across China and Germany and serving over 100 biopharma clients worldwide. Our capabilities span six advanced solution areas: Innovative Drug Solutions, Biosimilar Solutions, ATMP Solutions (including oncolytic viruses, CAR-T cell therapies, LBPs, and exosome-based therapies), Biologics Solutions for Companion Animals, Biologics Solutions for Livestock and Poultry, and Recombinant Products for Healthcare & Lifestyle. Supported by robust quality systems aligned with EMA, FDA, and NMPA standards, we enable the development of even the most challenging-to-express proteins. We drive bioprocess innovation through high-titer expression platforms (up to 39 g/L), next-generation cell lines, proprietary vector systems, and accelerated DNA-to-BLA timelines.
Read more

About me

I obtained my Ph.D. in Biotechnology from Sun Yat-sen University in 2013. I accumulated 9 years of working experience at Wens Food Group, where I led the R&D of genetically engineered subunit vaccines. Over the past 5 years at Canton Biologics, I have been in charge of veterinary biological product development, covering antigen research for farm animal subunit vaccines and innovative drug development for companion animals.

Additional questions

Interests

VaccinesRegulatory AffairsLivestockFinancing / Investment / FundingEnabling technology (assay, delivery, formulation, manufacturing, ...)Companion animals

What is your primary goal for attending this event?

Exploring potential collaborationsLearning about the latest trends in healthtechUnderstanding regulatory and policy developments